The Central Nervous System as a Sanctuary Site in ALK-Positive Non–Small-Cell Lung Cancer
- 1 December 2013
- journal article
- case report
- Published by Elsevier BV in Journal of Thoracic Oncology
- Vol. 8 (12), 1570-1573
- https://doi.org/10.1097/jto.0000000000000029
Abstract
No abstract availableKeywords
This publication has 17 references indexed in Scilit:
- Crizotinib versus Chemotherapy in AdvancedALK-Positive Lung CancerThe New England Journal of Medicine, 2013
- CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1-2 studyThe Lancet Oncology, 2013
- Taking Aim at ALK Across the Blood–Brain BarrierJournal of Thoracic Oncology, 2013
- Intramedullary Spinal Cord Metastases: A 20-Year Institutional Experience with a Comprehensive Literature ReviewWorld Neurosurgery, 2013
- Local Ablative Therapy of Oligoprogressive Disease Prolongs Disease Control by Tyrosine Kinase Inhibitors in Oncogene-Addicted Non–Small-Cell Lung CancerJournal of Thoracic Oncology, 2012
- ALK inhibitor crizotinib combined with intrathecal methotrexate treatment for non-small cell lung cancer with leptomeningeal carcinomatosisLung Cancer, 2012
- CSF Concentration of the Anaplastic Lymphoma Kinase Inhibitor CrizotinibJournal of Clinical Oncology, 2011
- Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung CancerThe New England Journal of Medicine, 2010
- Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancerNature, 2007
- Leptomeningeal carcinomatosisCancer Treatment Reviews, 1999